Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP933214.RAA8mHrvlZ6naslJ907Z1X6Ej26NPH7CQTg-e82HqAVt0130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933214.RAA8mHrvlZ6naslJ907Z1X6Ej26NPH7CQTg-e82HqAVt0130_provenance.
• NP434741.RAh2za-kyePY5llTtI9q-zw2yoVy4zYsqUPSenbJvhPn0130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP434741.RAh2za-kyePY5llTtI9q-zw2yoVy4zYsqUPSenbJvhPn0130_provenance.
• NP635649.RAOViZRwtGvb6ckG0UIjEFT5-wjvHXuosmCMzqZy6DTMc130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP635649.RAOViZRwtGvb6ckG0UIjEFT5-wjvHXuosmCMzqZy6DTMc130_provenance.
• assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP328172.RAS7wKy4ZkinWhA_MVmEGy0SAuzyTaQmES9E4_yPvTE3g130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328172.RAS7wKy4ZkinWhA_MVmEGy0SAuzyTaQmES9E4_yPvTE3g130_provenance.
• NP328170.RAPML2fe4SP5fbOw5VO3qqdL5Uv3aWxHWZ_1iYsPSJisM130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328170.RAPML2fe4SP5fbOw5VO3qqdL5Uv3aWxHWZ_1iYsPSJisM130_provenance.
• NP328167.RAtvPIL8IkasJe8w52t3saucutPu8V-apEEMun0Gsi0Bw130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328167.RAtvPIL8IkasJe8w52t3saucutPu8V-apEEMun0Gsi0Bw130_provenance.
• NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_provenance.
• NP328169.RAiRj6udOhsF2yj2X3w7YEAbimpCLG9BzM4_WVecrA69s130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328169.RAiRj6udOhsF2yj2X3w7YEAbimpCLG9BzM4_WVecrA69s130_provenance.
• NP328171.RAlgJB1vcU6AZRB2mioJJt5i__m92ZRHto1W-tdqja9VI130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328171.RAlgJB1vcU6AZRB2mioJJt5i__m92ZRHto1W-tdqja9VI130_provenance.